

23. (Amended) Use of a chemical compound represented by the general formula I of claim 1, or a pharmaceutically-acceptable addition salt thereof, for the manufacture of a pharmaceutical composition for the treatment or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease disorder or condition is responsive to modulation of SKCa, IKCa and/or BKCa channels.

24. (Amended) A method of treatment or alleviation of a disease or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to modulation of SKCa, IKCa and/or BKCa channels, comprising the step of administering to such a living animal body, including a human, in need thereof a therapeutically effective amount of a chemical compound represented by the general formula I of claim 1, or a pharmaceutically-acceptable addition salt thereof.

FILED
10/25/01
SUB
DI